Qlife enters fully funded feasibility deal with global pharma company for Egoo Health biomarker application

Reuters2026/08/26 06:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Qlife entered a fully funded feasibility agreement with a global pharma company on June 1, 2026 to test Egoo Health.
Revenue for Q2 2026 rose to SEK 728,000 from SEK 104,000, driven by the contracted feasibility study.
Project work progressed as planned, with final deliveries expected after the summer and talks planned on a next-stage collaboration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qlife Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 202608260230BITN____UKPR__SV_20260825-BIT-1685-0) on August 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Qlife enters fully funded feasibility deal with global pharma company for Egoo Health biomarker application

You may also like

Crypto prices